Results Validate Findings of Initial Study; End Points Achieved with No Intraoperative Adverse Events Management Presenting at Needham Growth Conference Today at 2:00pm ET HINGHAM, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) — The continued progression of Microbot Medical Inc.’s (Nasdaq: MBOT) LIBERTY™ Robotic System was further demonstrated as the Company announced […]
Other News
Marizyme Announces Approval for DuraGraft® in India
Latest Approval Joins a Growing List of Countries for Commercial Sales in 2021 JUPITER, Fla., Jan. 14, 2021 /PRNewswire/ — Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that its flagship product DuraGraft® is […]
Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure
THE WOODLANDS, Texas, Jan. 14, 2021 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has received U.S. Food and Drug Administration (FDA) regulatory feedback that the results of its SOLOIST and SCORED Phase 3 clinical studies can support a new drug application (NDA) submission for an indication to […]
BioSig PURE EP System Featured in the Editorial of EP Lab Digest
Westport, CT, Jan. 14, 2021 (GLOBE NEWSWIRE) — Leading industry publication calls attention to ongoing challenges in the electrophysiology lab PURE EP System is highlighted as a novel technological solution BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed […]
HCPLive® Adds The American Society for Preventive Cardiology to Its Strategic Alliance Partnership Program
CRANBURY, N.J.–(BUSINESS WIRE)–HCPLive® and The American Journal of Managed Care® (AJMC®) are excited to announce the addition of The American Society for Preventive Cardiology (ASPC) to their Strategic Alliance Partnership (SAP) programs. “We’re very honored to be able to join forces with ASPC to help promote the prevention of cardiovascular disease,” said Mike Hennessy Jr., […]
Elixir Medical Announces First Patient Treated in BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System
International Trial to Compare Bioadaptor, a Novel Coronary Artery Implant Designed to Adapt to Vessel Physiology, with Traditional Drug Eluting Stents MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the first patient has been treated in the BIOADAPTOR randomized controlled trial (RCT) of the DynamX™ […]
ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program
– Fourth-quarter 2020 U.S. net product revenue estimated between $8.0 and $8.5 million – – Range represents over 140 percent sequential growth for NEXLETOL® (bempedoic acid) tablets and NEXLIZET® (bempedoic acid and ezetimibe) tablets – – Company provides full-year 2021 operating expense guidance – – In-licensed oral PCSK9 inhibitor program furthers ESPERION […]
Acutus Medical Reports Preliminary, Unaudited Fourth Quarter and Full Year 2020 Results
CARLSBAD, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported preliminary unaudited revenue results for the quarter and full year ended December 31, 2020. Preliminary Fourth Quarter and Full […]
Cytokinetics Announces First Patient Dosed in Cohort 2 of Redwood-HCM
Company Earns $2.5 Million Milestone Payment from Ji Xing Pharmaceuticals SOUTH SAN FRANCISCO, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Inc. (Nasdaq: CYTK) today announced that the first patient has been dosed in Cohort 2 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), an ongoing Phase 2 clinical trial of […]
Positive preliminary data from Acarix’s exploratory heart failure study SEISMO
Press release Malmö, Sweden, January 13, 2021 Positive preliminary data from Acarix’s exploratory heart failure study SEISMO Acarix AB (publ) today announced positive preliminary data from the exploratory SEISMO study, using its modified CADScor®System on a potential heart failure application. The SEISMO trial was initiated in June 2018 to evaluate […]
Recent
Nyra Medical Receives Prestigious Jon DeHaan Foundation Award for Innovation in Cardiology at EuroPCR 2026
AHN’s Allegheny General Hospital Unveils New, State-of-the-Art Cardiac Cath and Electrophysiology Labs, following Completion of $19 Million Renovation Project
egnite Expands Medical Advisory Board with Three Nationally Recognized Cardiovascular Specialists
Popular
- No commented posts yet